A new investigational approach is now being studied.
For many osteoarthritis patients, treatment options have traditionally focused on temporary symptom management or eventual total knee replacement. SVF Cell Injection Therapy is being evaluated as a potential drug-free, surgery-free approach for knee osteoarthritis.
While existing treatments can help manage symptoms, many patients and physicians continue searching for options that may provide meaningful long-term improvement.
That is why investigational therapies like SVF Cell Injection Therapy are being studied.
Corticosteroid and hyaluronic acid injections may provide temporary relief for some individuals. Results and duration of relief can vary, and some patients continue to experience pain over time.
Other regenerative approaches, such as PRP and stem cells, are still being studied and are often not covered by insurance.
For some patients, knee replacement surgery may become an option. Although commonly performed, recovery can be significant and outcomes vary from patient to patient.
Studies show that nearly 1 in 3 patients is still unsatisfied with their level of pain relief at the 1-year mark.
GID BIO’s SVF Cell Injection Therapy is being studied as a new kind of injection that produces long-term, lasting pain relief using the healing cells from your own body.
In recent FDA clinical studies, patients who received a single injection demonstrated the following improvements at the 1-year follow-up.
Unlike current treatments, which introduce a foreign substance into your body, GID BIO’s investigational SVF Cell Injection is being studied as a therapy that uses the healing cells from your own body to reduce knee pain and restore function.
Utilizes your own cells. No surgery. No overnight hospital stay. The procedure is designed to be performed in an outpatient setting without joint replacement surgery or an overnight hospital stay.
This therapy is currently under investigation and has not been approved for commercial use. Ask your physician whether participation in an investigational treatment program may be appropriate for you.
Living with knee osteoarthritis can impact the activities, routines, and moments that matter most.
SVF Cell Injection Therapy is currently being studied as an investigational approach that may help expand future treatment possibilities for patients seeking alternatives beyond traditional surgery.
Get back in the garden.
Travel without fear.
Sleep through the night without pain.
Enjoy your favorite activities again.
David Elson, USA
David Elson, USA
David Elson, USA
Adipose (fat) tissue, the kind that lives just under the skin of your belly or hip, stores a remarkable collection of natural healing cells. These cells are what your body already sends to repair damaged tissue.
During the procedure, a small amount of your own fat tissue is collected, filtered, and concentrated, ready for injection into the knee joint.
We are studying whether these cells calm inflammation and allow the body’s natural healing response to do its work.
When approved in the future, GID BIO’s SVF Cell Injection Therapy is intended to be performed in an outpatient setting without an overnight hospital stay.
When approved, GID BIO’s SVF Cell Injection Therapy may be accessible through Medicare and private insurers.
GID BIO’s SVF Cell Injection Therapy has completed a Phase 3 FDA clinical trial, one of the most stringent test protocols in medicine. We have more steps to take before the treatment is approved, but this critical Phase 3 trial reported no complications from the device, no device-related infections, and no unexpected serious side effects.
From start to finish, everything happens in your outpatient treatment center or physician’s office, and the process takes around 3 hours to complete.
GID BIO’s SVF Cell Injection Therapy is currently under FDA review and is not yet commercially available.
Using imaging guidance to ensure accurate placement, your physician injects the solution into your knee joint, and you are discharged the same day.
SVF Cell Injection Therapy is currently under investigation and not yet available for commercial use. Join our mailing list to receive updates about clinical research progress and future developments.
